SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE)-- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...

SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...

Title: The DARE to PLAY™ Difference Date: Monday, November 17, 2025Time: 12:00pm ETRegistration and Access: https://cvent.me/KO1obd DARE to PLAY™ Sildenafil Cream is a first-of-its-kind topical ...

Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license agreement SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré ...

President & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value ...

SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE)-- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...

Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and ...

SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE)-- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO ...

DARE to PLAY™ Sildenafil Cream is a first-of-its-kind topical sildenafil formulation designed specifically for women to enhance genital blood flow and arousal response. Supported by clinical data ...